Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220994 | 1.00 | PRKAA2 (0.57) | PRKAA2SIGMAR1ACHEBCHEDRD2 | |
| SCHEMBL4217260 | 0.94 | PRKAA2 (0.51) | PRKAA2SIGMAR1ACHEBCHEDRD2 | |
| SCHEMBL4217265 | 0.94 | PRKAA2 (0.51) | PRKAA2SIGMAR1ACHEBCHEDRD2 | |
| SCHEMBL4223541 | 0.90 | SIGMAR1 (0.61) | PRKAA2SIGMAR1ACHEDRD2HTR2A | |
| SCHEMBL4223535 | 0.90 | SIGMAR1 (0.61) | PRKAA2SIGMAR1ACHEDRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4231071 | 0.89 | PRKAA2 (0.54) | PRKAA2SIGMAR1ACHEBCHEDRD2 | |
| Hydrochloric Acid SCHEMBL4231076 | 0.89 | PRKAA2 (0.54) | PRKAA2SIGMAR1ACHEBCHEDRD2 | |
| SCHEMBL4223333 | 0.84 | JAK2 (0.49) | SIGMAR1ACHEBCHEDRD2HTR2A | |
| SCHEMBL5196321 | 0.84 | JAK2 (0.49) | SIGMAR1ACHEBCHEDRD2HTR2A | |
| SCHEMBL4223338 | 0.84 | JAK2 (0.49) | SIGMAR1ACHEBCHEDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | PRKAA2 585/4885SIGMAR1 1585/4885ACHE 4051/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | PRKAA2 707/4885SIGMAR1 1514/4885ACHE 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.